News
Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...
BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...
Zacks Investment Research on MSN1d
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global ...
BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...
Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...
Stocktwits on MSN5d
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer DrugShares of BionNTech SE (BNTX) jumped 13% in Monday’s pre-market after the company announced that it has entered into an ...
GlobalData on MSN5d
BMS outlays $11bn to join BioNTech’s development of bispecific cancer drugBristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...
Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.
BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones ...
5don MSN
Bristol Myers Squibb just agreed to shower BioNTech with cash. BioNTech ( BNTX 20.01%), one of the companies made famous for ...
BioNTech and Bristol Myers Squibb have announced a partnership for the global co-development and co-commercialization of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, which aims to ...
5don MSN
Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback